Biocat, BioRegion of Catalonia’s Post

📆 PHRAKTION’S NEXT PEER-TO-PEER WEBINAR: Science is brilliant - Why the heck I need Commercial input during drug development? Thursday 13th June 2024 at 4pm BST. 🔗 To register please click on the link below: https://lnkd.in/esAf5Fv8 In the latest of phraktion's Peer-to-Peer webinar series featuring pharma industry leaders, we are delighted to be joined by phraktion partner, Dr Sanjay Khandekar. Regulatory approval of medicines is no longer enough to ensure commercial success. HCPs and Payors are demanding innovative, high value drugs to achieve effective cost reductions which is becoming a major hurdle for the commercialization of new medicines. Providing real world examples, Sanjay will delve into the necessity of well thought out commercial considerations when developing medicines of value. Sanjay is a seasoned life science / biopharma leader with 30+ years of combined R&D and global marketing experience bridging R&D and Commercial and both strategy and execution. His experience includes shaping and driving development of 15+ early to mid-stage oncology assets and developing go-to-market and life cycle management strategies for 5 late-stage / marketed products. #expert #pharma #fractional

Let us take a look at the global pharma industry R&D pipeline: Pfizer is currently leading the pack with over 100 programs, including a strong emphasis on oncology, but also vaccines and metabolic & inflammatory indications. And also AstraZeneca stands out with its impressive suite of Phase 3 assets, signaling a variety of launches to come to market in the near future. The company expects 10 programs thereof to have “blockbuster potential.” The graph also points to the strong global footprint of the industry and its innovation capability. The pipeline is not dominated by players only from one continent. While the USA are famous for very strong contributions to pharma R&D spend as well as innovation output, the top 10 list also features players from Asia and Europe. And of course, the companies operate internationally with integrated innovation networks inside and outside of their own organizations and HQ countries. Roland Berger Belgium happily supports local and international Pharmaceutical players navigate their most critical challenges. Please feel free to contact our experts: Grégoire Tondreau Astrid Böhlke Maxime Descy Michael Baur #RolandBerger #RBHealthBelgium #Innovation #Pharma #LifeScience #R&D

👀 The new Pharma Innovation Index is out and Novo Nordisk is at the top of 2024 ranking! Is Ozempic the most “innovative" drug ever...and who are the top innovators? 💊 IDEA's latest Innovation & Invention Index for 2024 unveils some exciting shifts among the leading Pharma giants. Let’s take a look at the top innovators & their breakthroughs: 🥇 Novo Nordisk: Boasting a revenue increase of over 30% in 2023, 90% of which come from the success of its flagship GLP-1 semaglutide (Ozempic and Wegovy). 🥈GSK: Spearheaded by revenue growth and increased R&D investment, GSK showcased pioneering treatments like Jesduvroq for chronic kidney disease and Arexvy, a pivotal RSV vaccine. 🥉Pfizer: Despite facing financial challenges due to declining sales, Pfizer remains a frontrunner in pharmaceutical innovation, exemplified by groundbreaking advancements like Paxlovid and Zavzpret. Eli Lilly and Company: Seeing a big jump in revenue and a nearly 30% rise in R&D spending, the company made progress in diabetes and cancer care, securing new approvals for Jardiance and Jaypirca! Bristol Myers Squibb: Despite a modest decrease in R&D spending, the company achieved a pipeline-to-portfolio ratio of nearly 400%! For the top 30 pharma companies in 2023; 💰 It cost an average of ~$5.7 billion to launch a new drug. But with over $825 billion in global revenue, the investment pays off! 🔬 23% of global revenue is dedicated to R&D, contributing to the development of 187 Orphan Drugs, 120 Fast Tracks, and 52 Breakthrough Therapies. #PharmaInnovation #Healthcare #IDEAIndex #Biotech #Medicinem #Lifesciences #Innovation ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting industry experts, ex-payors and KOLs with strategy consulting firms and investors in life sciences and healthcare for 1h calls or consulting assignments. Register as expert: https://lnkd.in/d66dhd4Y Book an intro call: https://lnkd.in/dk-cVS87 Like my content? Join 13k+ followers by clicking my name + follow + 🔔

Uncovering Hidden Costs in nAMD Clinics In the quest for cost-effectiveness, are we missing a crucial piece of the puzzle? Our latest publication "Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis" published in Current Medical Research and Opinion, reveals the significant strain costs impacting nAMD clinics, often overlooked in traditional cost-effectiveness analyses. In our scenario analysis, Drug A may appear cheaper with a lower upfront cost (£10), the associated strain costs (£13,115) paint a different picture compared to Drug B (£100 upfront with no additional strain costs). What does this mean? • Drug A: Lower initial cost but significant long-term strain costs. • Drug B: Higher initial cost but no additional strain costs. Impact on decision-making: When evaluating options, it's essential to consider not just the drug costs, but also the broader economic impact on the service as a whole. Incorporating strain costs into Health Technology Assessments (HTA) provides a more comprehensive view, ensuring sustainable and efficient healthcare delivery. Read the full article to explore our findings and methodology in detail: https://lnkd.in/d2-gjXba Get in touch with Medialis Ltd at [email protected] to help shift your focus to more holistic evaluations that account for all costs, fostering better decision-making and improved patient care. Join the conversation and share your insights on how we can better integrate these findings into our practices. #nAMD #HealthcareEconomics #CostEffectiveness #HTA #HealthcareInnovation #nASInstrument #DiseaseSpecific Ascendis Pharma, AstraZeneca, Biogen, BioMarin Pharmaceutical Inc., bluebird bio, Bristol Myers Squibb, Chinook Therapeutics, Clementia Pharmaceuticals, Daiichi Sankyo US, Eli Lilly and Company, Genentech, GenSight Biologics, GSK, Roche, Immungenetics AG, ImmunityBio, Inc., Incyte, Insmed Incorporated, Ionis Pharmaceuticals, Inc., Ipsen, Janssen Inc., MediciNova, Inc., Merck, MSD Merck Sharp & Dohme A.G., Neuren Pharmaceuticals Limited, NS Pharma, Inc., Novartis, Novo Nordisk, Pfizer, QED PHARMACEUTICALS PVT LTD, Reata Pharmaceuticals, Inc., Regeneron, Rigel Pharmaceuticals Inc., RIVER RENAL SERVICES, INC., IQVIA, Sanofi, Takeda, Travere Therapeutics, Ultragenyx

🌐 Pharma Forum Oct. 14, 2024: Key Highlights from This Weekend https://wix.to/ZV1Cyt9 1️⃣ Mubadala's KELIX Bio Expands with Major Acquisition: KELIX Bio, a subsidiary of Mubadala, has acquired four pharma assets from GlobalOne Healthcare Holdings, further solidifying the UAE's role as a key player in the global life sciences sector. This move is part of the UAE’s broader economic diversification strategy. 2️⃣ Pfizer and BioNTech Pause Flu-COVID Combo Vaccine Development: Development challenges have led Pfizer and BioNTech to halt their work on a combined flu-COVID vaccine. A sign of the evolving vaccine market post-pandemic. 3️⃣ Novo Nordisk Targets New Uses for GLP-1 Agonists: Following the success of GLP-1 drugs like Wegovy, Novo Nordisk is investigating their potential to treat conditions such as Polycystic Ovary Syndrome (PCOS), offering hope for expanded therapeutic applications. 4️⃣ Bayer Wins Major Roundup Legal Battle: In a significant court ruling, Bayer triumphed over cancer claims related to its Roundup weedkiller, leading to a surge in market confidence and share prices. 5️⃣ FDA Approves Gilead’s Liver Disease Drug: Gilead continues its growth in liver disease treatments, securing FDA approval for a drug following a $4.3 billion acquisition, underscoring the power of strategic acquisitions. Stay updated on these impactful changes shaping the biotech and pharma landscape! #Biotech #Pharma #Healthcare #DrugDevelopment #Innovation #LifeSciences

𝘾𝙖𝙣𝙘𝙚𝙧 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝘿𝙧𝙪𝙜 𝙈𝙖𝙧𝙠𝙚𝙩 2024-2030. 𝙂𝙡𝙤𝙗𝙖𝙡 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙍𝙚𝙥𝙤𝙧𝙩 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗲𝗺𝗮𝗻𝗱. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/deKKdb4v The report offers a comprehensive overview of the Cancer Targeted Drug industry, detailing its development along the industry chain and assessing market statuses in various sectors including Hospital and Retail Pharmacy, with a focus on Sorafenib and Lenvatinib. It highlights key enterprises in both developed and developing markets, analyzing technological advancements, patents, applications, and market trends. Regionally, North America and Europe show steady growth propelled by government initiatives and rising consumer awareness, while Asia-Pacific, notably China, leads globally due to strong domestic demand, supportive policies, and robust manufacturing capabilities. Providing insights into market dynamics, challenges, and opportunities, the report presents a holistic understanding of the Cancer Targeted Drug market and its stakeholders. *𝗕𝘆 𝗧𝘆𝗽𝗲: Sorafenib, Lenvatinib, Regorafenib, Osimertinib, Anlotinib, Other *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospital, Retail Pharmacy, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Bayer, Eisai US, Zelgen Biopharmaceuticals, Cipla, NATCO Pharma , AstraZeneca, Novartis, Roche, Bristol Myers Squibb, Pfizer, Beacon Pharmaceuticals PLC, YaoPharma Co., Ltd., CSPC Pharmaceutical Group , Simcere Pharmaceutical Group #CancerTreatment #TargetedTherapy #PrecisionMedicine #Oncology #DrugDevelopment #CancerResearch #PersonalizedMedicine #Pharmaceuticals #ClinicalTrials #HealthcareInnovation

SOMAÍ Pharmaceuticals proudly announces a strategic partnership with GROW® Pharma . This collaboration marks a significant milestone for SOMAÍ Pharmaceuticals as it expands its global presence to the UK, following successful entrances to Australian, German, and Polish markets with strategic partnerships earlier this year. Under the two-year agreement, SOMAÍ will create access to its differentiated cannabinoid-containing product portfolio for all the UK-based medical cannabis-prescribing clinics and doctors, utilizing Grow Pharma’s extensive distribution network. SOMAÍ expects to generate € 750k revenue in sales in the first year of this contract. "We are excited to partner with Grow Pharma to expand our reach to the UK clinics equally and introduce them to SOMAÍ innovative cannabis-based medical products with different tastes and terpene mixes. By navigating the intricate regulatory landscape, SOMAÍ aims to provide innovative solutions for patients grappling with conditions such as chronic pain, epilepsy, and multiple sclerosis. Through strategic partnerships, rigorous research initiatives, and advocacy efforts, SOMAÍ is committed to enhancing patient access and empowering them with carefully crafted medications that have the potential to transform their lives," said Michael Sassano, a Founder and CEO of SOMAÍ Pharmaceuticals. "We are thrilled and honoured to partner with SOMAÍ Pharmaceuticals. From our very first meeting, Michael and I recognised the immense potential in collaborating because of our similar attitudes to patient care. We admire their unwavering commitment to making a positive impact and their dedication to providing a broad range of medicines to meet diverse patient needs. We are very excited to work together and to significantly improve the portfolio of available medicines for UK patients”, said Pierre van Weperen, CEO of Grow Pharma. Read more: https://lnkd.in/g9vZGScJ #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews #medicalcannabisEU #medicalcannabisaustralia

How To Use #AI To Increase #PatientAdherence? In this episode of #AIForPharmaGrowth, Dr. Andrée Bates is joined by Eric Doherty. #Increasingoutcomes? #Increasingeffectiveness of #clinicaltrials? #Reducingcosts? #Reducingtime? Improving the lives of many. They speak about how #AI is improving patient adherence. https://lnkd.in/eiciScmc Johnson & Johnson Pfizer Roche Merck Merck Group AbbVie Abbott Bayer Sanofi AstraZeneca NovartisBristol Myers Squibb GSK Eli Lilly and Company Novo Nordisk Takeda Amgen Boehringer Ingelheim Gilead Sciences Siemens Siemens Healthineers GE HealthCare Teva Pharmaceuticals KenvueViatris Baxter International Inc. Haleon Regeneron Astellas Pharma Amgen Parexel Worldwide Clinical Trials Medpace Premier Research Novotech Clinipace Crown Bioscience SAS

Hyperkalemia Treatment Market Research: Key Players Spotlight 📈 Vifor Pharma: Leading the way in hyperkalemia management with innovative therapies that address potassium imbalances. Their commitment to advancing treatment options is shaping the future of patient care. #ViforPharma 💊 AstraZeneca: Known for its cutting-edge research and development, AstraZeneca continues to make significant strides in hyperkalemia treatments, offering solutions that enhance patient outcomes. #AstraZeneca 🧪 Sanofi: A global leader in pharmaceuticals, Sanofi’s dedication to developing effective hyperkalemia therapies reflects their broader mission to improve patient health worldwide. #Sanofi 🔬 CMP Pharma: With a focus on specialized treatments, CMP Pharma is contributing valuable advancements in the management of hyperkalemia, addressing critical needs in the healthcare landscape. #CMPPharma 💼 Belcher Pharmaceuticals: Pioneering new approaches to hyperkalemia treatment, Belcher Pharmaceuticals is committed to providing high-quality solutions that support patient health and well-being. #BelcherPharmaceuticals #Healthcare #Pharmaceuticals #MedicalResearch #PatientCare #Innovation #Treatment #MarketResearch #HealthcareTrends #MedicalDevices #DrugDevelopment #Hyperkalemia #MarketResearch #PharmaIndustry #MedicalResearch #TreatmentOptions #PotassiumImbalance #HealthcareInnovation #DrugTherapy #PatientOutcomes #Pharmaceuticals Read Report @ https://lnkd.in/g4BXYCgA

Real-world evidence (RWE) is revolutionising the healthcare environment. RWE is crucial for accelerating patient access to medications, broadening the scope of eligible patients at the time of regulatory approval, and enabling healthcare providers to initiate treatments more swiftly with robust, data-driven insights. The importance of RWE highlights the necessity for a clear and scientifically robust definition. We are proud to have contributed to this field by offering the only scientifically derived and peer-reviewed RWE benchmark in published literature. This precise definition is essential for professionals dedicated to generating and applying RWE to enhance patient care. Read our publication for more details: https://lnkd.in/dBCkKYb7 We extend our gratitude to the Medical Affairs Pharmaceutical Physicians (MAPP) advisory panel and all contributors to this significant work: Dr. Andrew Pain, Daniel Franks, Dani Thomas, Gerd Möller, MD, PhD, Health Economist, John Bolodeoku, Lisa Moore-Ramdin, Peter Stonier, Raj Rout, Tim P. William Spencer, Michael Smyth, Pundalik Nayak, Judith Livingstone, Guy Yeoman, Jan Sabbat, Philip Cruz, Maciej D. Zatonski, and Arun Mistry. For more information about our RWE initiatives or to learn how our medicine adoption model can help you get more patients on new medicines sooner, please email us at [email protected]. #RealWorldEvidence #PatientCare #MedicalAffairs #MarketAccess #RWE #RareDiseases #PatientOutcomes Ascendis Pharma, AstraZeneca, Biogen, BioMarin Pharmaceutical Inc., bluebird bio, Bristol Myers Squibb, Chinook Therapeutics, a Novartis Company, Clementia Pharmaceuticals, Daiichi Sankyo US, Eli Lilly and Company, Genentech, GenSight Biologics, GSK, Roche, Immungenetics AG, ImmunityBio, Inc., Incyte, Insmed Incorporated, Ionis Pharmaceuticals, Inc., Ipsen, Janssen Inc., MediciNova, Inc., Merck, MSD Merck Sharp & Dohme A.G., Neuren Pharmaceuticals Limited, NS Pharma, Inc., Novartis, Novo Nordisk, Pfizer, QED PHARMACEUTICALS PVT LTD, Reata Pharmaceuticals, Inc., Regeneron, Rigel Pharmaceuticals Inc., RIVER RENAL SERVICES, INC., IQVIA, Sanofi, Takeda, Travere Therapeutics, Ultragenyx